Mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma
- PMID: 35803285
- DOI: 10.1016/S1470-2045(22)00385-0
Mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma
Conflict of interest statement
I report consulting fees, payments, or honoraria for lectures from, and participation in advisory boards of, Roche, Pfizer, Janssen, Hexal, Celltrion, AbbVie, Novartis, Bayer, and Beigene; participation on a data safety monitoring board from Morphosys and Regeneron; research funding from Roche, Janssen, Celltrion, AbbVie, Bayer, Amgen, and MSD; and membership in the steering committee of the guideline committee in the European Society for Medical Oncology.
Comment on
-
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.Lancet Oncol. 2022 Aug;23(8):1055-1065. doi: 10.1016/S1470-2045(22)00335-7. Epub 2022 Jul 5. Lancet Oncol. 2022. PMID: 35803286 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources